Category Archives: Patent Term Extension

Avoid Patent Clauses in Trade Treaties that can Kill Millions

By Martin Khor, Inter Press Service | February 27, 2017 PENANG, Feb 27 2017 (IPS) – Recently a very interesting article on why there are inequalities in access to health care and how  medicine prices are beyond the reach of many … Continue reading

Posted in Data Exclusivity, FTA, Patent Term Extension, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

RCEP and Health: This Kind of ‘Progress’ is Not What India and the World Need

Source: The Wire Concerns remain over the impact of RCEP negotiations on public health and access to medicines Negotiators from 16 countries are meeting in Kobe, Japan on Monday to begin the 17th round of negotiations of the Regional Comprehensive Economic … Continue reading

Posted in Data Exclusivity, Investor state dispute, IPR, Patent, Patent Term Extension, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

Civil society, patient groups call on Japan and South Korea to withdraw harmful proposals from RCEP negotiations

By Ramesh Shankar, http://www.pharmabiz.com | February 24, 2017 As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet next week in Kobe, Japan, for the seventeenth round of negotiations, civil society and patient groups, including the international medical humanitarian … Continue reading

Posted in Data Exclusivity, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

MSF calls on Japan and South Korea to drop the harmful RCEP measures

Kobe, Japan/New Delhi 22 February 2017 As 16countries negotiating the Regional Comprehensive Economic Partnership (RCEP)agreement meet next week in Kobe, Japan, for the seventeenth round of negotiations, international medical humanitarian organisation Médecins Sans Frontières (MSF) is appealing tothe Japanese and South … Continue reading

Posted in Data Exclusivity, Drug prices, Generics, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment

TPP is dead, but its legacy lives on

By Arjun Jayadeva, The HinduThe Hindu | February 9, 2017 The Trans-Pacific Partnership was dead long before Donald Trump signed his executive order. But its damaging aspects, like stringent IP provisions, have just migrated to other agreements U.S. President Donald Trump’s … Continue reading

Posted in Data Exclusivity, Evergreening, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, Uncategorized | Leave a comment

European Commission publishes negotiating proposals for EU-Indonesia trade deal

It is important to note that the EU proposals on IP are TRIPS-plus in multiple regards and would surely reduce policy space in Indonesia and negatively impact access to affordable medicines.  Even a preliminary review of the proposal reveals: A … Continue reading

Posted in IPR Enforcement, Patent Term Extension, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Refuse trade, investment provisions that threaten access to affordable meds

Positive Malaysian Treatment Access & Advocacy Group (MTAAG+) calls on the Malaysian government to reject trade and investment agreement provisions that threaten access to affordable medicines. MTAAG+ asserts the need to make its position and demand known because of the … Continue reading

Posted in Data Exclusivity, Patent Term Extension, Regional Comprehensive Economic Partnership, TPP, TRIPS, TRIPS plus, Uncategorized | Leave a comment